Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience.

Brendan J Guercio Michal Sarfaty Min Yuen Teo Neha Ratna Cihan Duzgol Samuel A Funt Chung-Han Lee David Henry Aggen Ashley M Regazzi Zhiyu Chen Michael Lattanzi Hikmat A Al-Ahmadie Angela Rose Brannon Ronak H Shah Carissa E Chu Andrew T Lenis Eugene J Pietzak Bernard H Bochner Michael F Berger David B Solit Jonathan E Rosenberg Dean F Bajorin Gopakumar V Iyer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

FGFR3 mutations are common in urothelial carcinoma, whereas FGFR2 alterations are rare. Discordance of FGFR3 mutational status between primary and metastatic tumors occurs frequently and raises concern over sequencing archival primary tumors to guide patient selection for erdafitinib therapy. Erdafitinib responses were typically brief and dosing was limited by toxicity. FGFR3, AKT1, and TP53 mutations detected in cfDNA represent putative mechanisms of acquired erdafitinib resistance.

Keyphrases